139 related articles for article (PubMed ID: 30989775)
21. Pharmacokinetics of initial full and subsequent reduced doses of S-1 in patients with locally advanced head and neck cancer-effect of renal insufficiency.
Yamazaki T; Tahara M; Enokida T; Wakasugi T; Arahira S; Zenda S; Motegi A; Akimoto T; Yoshisue K
Jpn J Clin Oncol; 2017 May; 47(5):407-412. PubMed ID: 28159957
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
[TBL] [Abstract][Full Text] [Related]
24. Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.
Fujita K; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Sasaki Y
Ann Oncol; 2009 May; 20(5):946-9. PubMed ID: 19150953
[TBL] [Abstract][Full Text] [Related]
25. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
26. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
[TBL] [Abstract][Full Text] [Related]
27. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
29. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
[TBL] [Abstract][Full Text] [Related]
30. [Phase I study of S-1. S-1 Study Group].
Taguchi T; Inuyama Y; Kanamaru R; Hasegawa K; Akazawa S; Niitani H; Furue H; Kurihara M; Ota K; Suga S; Ariyoshi Y; Takai S; Shimoyama T; Toge T; Takashima S; Sugimachi K; Hara Y; Fujita H; Kimura K; Saito T; Tsukagoshi S; Nakao I
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2253-64. PubMed ID: 9422070
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Blum M; Suzuki A; Ajani JA
Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Tahara M; Minami H; Kawashima M; Kawada K; Mukai H; Sakuraba M; Matsuura K; Ogino T; Hayashi R; Ohtsu A
Cancer Sci; 2011 Feb; 102(2):419-24. PubMed ID: 21134076
[TBL] [Abstract][Full Text] [Related]
33. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V
Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532
[TBL] [Abstract][Full Text] [Related]
34. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
[TBL] [Abstract][Full Text] [Related]
35. [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Huang DZ; Xiong JP; Xu N; Yan Z; Zhuang ZX; Yu Z; Wan HP; Zhang Y; Deng T; Zheng RS; Guo ZQ; Hu CH; Wang ML; Yu ZH; Yao Y; Meng JC; Ba Y
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):865-8. PubMed ID: 23291139
[TBL] [Abstract][Full Text] [Related]
36. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
37. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
Chollet P; Schöffski P; Weigang-Köhler K; Schellens JH; Cure H; Pavlidis N; Grünwald V; De Boer R; Wanders J; Fumoleau P;
Eur J Cancer; 2003 Jun; 39(9):1264-70. PubMed ID: 12763215
[TBL] [Abstract][Full Text] [Related]
39. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Ikeda M; Shiina S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Ueno H; Morizane C; Kondo S; Sakamoto Y; Asaoka Y; Tateishi R; Koike K; Arioka H; Okusaka T
Invest New Drugs; 2014 Oct; 32(5):928-36. PubMed ID: 24829073
[TBL] [Abstract][Full Text] [Related]
40. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Lim HS; Ryu KW; Lee JH; Kim YW; Ju Choi I; Kim MJ; Park YI; Hwang A; Park SR
J Clin Pharmacol; 2015 Aug; 55(8):926-35. PubMed ID: 25810324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]